Completed
Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia
What is being tested
Data Collection
Who is being recruted
Infections+2
+ Lung Diseases
+ Pneumonia
+7 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 3
Interventional
Study Start: May 2004
Summary
Principal SponsorNovartis Pharmaceuticals
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: May 1, 2004
Actual date on which the first participant was enrolled.The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Official TitleTifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia
Principal SponsorNovartis Pharmaceuticals
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
2136 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
InfectionsLung DiseasesPneumoniaRespiratory Tract DiseasesRespiratory Tract Infections
Criteria
2 inclusion criteria required to participate
Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence
Pneumonia of sufficient severity to require ICU admission and management
5 exclusion criteria prevent from participating
Pregnancy
Weight over 150 kg
Patients at increased risk of bleeding
Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center